Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting.

Alhawassi TM, Krass I, Bajorek BV, Pont LG.

Clin Interv Aging. 2014 Dec 1;9:2079-86. doi: 10.2147/CIA.S71178. eCollection 2014.

2.

Use of medications for secondary prevention in stroke patients at hospital discharge in Australia.

Eissa A, Krass I, Bajorek BV.

Int J Clin Pharm. 2014 Apr;36(2):384-93. doi: 10.1007/s11096-013-9908-3. Epub 2014 Feb 12.

PMID:
24519632
3.

Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population.

Alene M, Wiese MD, Angamo MT, Bajorek BV, Yesuf EA, Wabe NT.

BMC Clin Pharmacol. 2012 Jun 18;12:10. doi: 10.1186/1472-6904-12-10.

4.

Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Epub 2012 Jun 19. Review.

PMID:
22708668
5.

Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation.

Bajorek BV, Masood N, Krass I.

Australas J Ageing. 2012 Jun;31(2):102-9. doi: 10.1111/j.1741-6612.2011.00546.x. Epub 2011 Jul 28.

PMID:
22676169
6.

Stroke management: updated recommendations for treatment along the care continuum.

Wright L, Hill KM, Bernhardt J, Lindley R, Ada L, Bajorek BV, Barber PA, Beer C, Golledge J, Gustafsson L, Hersh D, Kenardy J, Perry L, Middleton S, Brauer SG, Nelson MR; National Stroke Foundation Stroke Guidelines Expert Working Group.

Intern Med J. 2012 May;42(5):562-9. doi: 10.1111/j.1445-5994.2012.02774.x.

PMID:
22616960
7.

Barriers to the utilization of thrombolysis for acute ischaemic stroke.

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Aug;37(4):399-409. doi: 10.1111/j.1365-2710.2011.01329.x. Epub 2012 Mar 4. Review.

PMID:
22384796
8.

Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now.

Bajorek BV, Ren S.

Int J Clin Pharm. 2012 Feb;34(1):88-97. doi: 10.1007/s11096-011-9594-y. Epub 2011 Dec 17.

PMID:
22179941
9.

Warfarin management after discharge from hospital: a qualitative analysis.

Stafford L, van Tienen EC, Peterson GM, Bereznicki LR, Jackson SL, Bajorek BV, Mullan JR, DeBoos IM.

J Clin Pharm Ther. 2012 Aug;37(4):410-4. doi: 10.1111/j.1365-2710.2011.01308.x. Epub 2011 Oct 20.

PMID:
22017213
10.

Clinical outcomes of a collaborative, home-based postdischarge warfarin management service.

Stafford L, Peterson GM, Bereznicki LR, Jackson SL, van Tienen EC, Angley MT, Bajorek BV, McLachlan AJ, Mullan JR, Misan GM, Gaetani L.

Ann Pharmacother. 2011 Mar;45(3):325-34. doi: 10.1345/aph.1P617. Epub 2011 Mar 8.

PMID:
21386021
11.

Retrospective evaluation of home medicines review by pharmacists in older Australian patients using the medication appropriateness index.

Castelino RL, Bajorek BV, Chen TF.

Ann Pharmacother. 2010 Dec;44(12):1922-9. doi: 10.1345/aph.1P373. Epub 2010 Nov 30.

PMID:
21119095
12.

Use of evidence-based therapy for the prevention of cardiovascular events among older people.

Castelino RL, Chen TF, Guddattu V, Bajorek BV.

Eval Health Prof. 2010 Sep;33(3):276-301. doi: 10.1177/0163278710374854.

PMID:
20801973
13.

Are interventions recommended by pharmacists during Home Medicines Review evidence-based?

Castelino RL, Bajorek BV, Chen TF.

J Eval Clin Pract. 2011 Feb;17(1):104-10. doi: 10.1111/j.1365-2753.2010.01375.x. Epub 2010 Aug 15.

PMID:
20722881
14.

Drug Burden Index and potentially inappropriate medications in community-dwelling older people: the impact of Home Medicines Review.

Castelino RL, Hilmer SN, Bajorek BV, Nishtala P, Chen TF.

Drugs Aging. 2010 Feb 1;27(2):135-48. doi: 10.2165/11531560-000000000-00000.

PMID:
20104939
15.

Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services.

Castelino RL, Bajorek BV, Chen TF.

Ann Pharmacother. 2009 Jun;43(6):1096-106. doi: 10.1345/aph.1L700. Epub 2009 May 26. Review.

PMID:
19470856
16.

Balancing risk versus benefit: the elderly patient's perspective on warfarin therapy.

Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I.

Pharm Pract (Granada). 2009 Apr;7(2):113-23. Epub 2009 Mar 15.

17.

The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation.

Perera V, Bajorek BV, Matthews S, Hilmer SN.

Age Ageing. 2009 Mar;38(2):156-62. doi: 10.1093/ageing/afn293. Epub 2009 Jan 16.

18.

Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.

Vermeer NS, Bajorek BV.

J Clin Pharm Ther. 2008 Dec;33(6):591-601. doi: 10.1111/j.1365-2710.2008.00950.x.

PMID:
19138236
19.

Failure to weigh patients in hospital: a medication safety risk.

Hilmer SN, Rangiah C, Bajorek BV, Shenfield GM.

Intern Med J. 2007 Sep;37(9):647-50.

PMID:
17714205
20.

Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers.

Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I.

Med J Aust. 2007 Feb 19;186(4):175-80.

PMID:
17309417
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk